Applied DNA Implements 1-for-50 Reverse Stock Split

Applied DNA Sciences, Inc. (NASDAQ:APDN), a leader in PCR-based DNA technologies, has announced a 1-for-50 reverse stock split. Effective from March 14, 2025, the company’s common stock will trade on a split-adjusted basis on The Nasdaq Capital Market. This move is aimed at complying with Nasdaq's $1 minimum bid price requirement for continued listing.

Upon implementation, Applied DNA's outstanding shares will decrease from approximately 55.2 million to 1.1 million. The authorized shares will, however, remain unchanged. Adjustments will affect options and warrants with no fractional shares issued, as they will be rounded up to the nearest whole number.

The decision for this reverse split was taken following stockholder approval in September 2024. Stockholders with questions are encouraged to contact their banks or brokers for more details about their holdings after the adjustment.